Go Pro
NASDAQ:BYSI

BeyondSpring Q1 2025 Earnings Report

BeyondSpring logo
$0.73 -0.01 (-1.85%)
Closing price 09/23/2026 03:59 PM Eastern
Extended Trading
$0.72 0.00 (-0.22%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeyondSpring EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BeyondSpring Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BeyondSpring Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Monday, May 12, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

BeyondSpring's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

BeyondSpring Earnings Headlines

How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its valuation has doubled since the announcement, with some estimates putting the company's worth near 3 trillion dollars by IPO day. Google, Amazon, Nvidia and Microsoft have all taken stakes, while Goldman Sachs, Morgan Stanley and JPMorgan are competing for private shares. Anthropic's annualized revenue reportedly grew 80 times in the first quarter alone. See how investors are positioning ahead of this closely watched IPO.tc pixel
See More BeyondSpring Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeyondSpring? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeyondSpring and other key companies, straight to your email.

About BeyondSpring

BeyondSpring (NASDAQ:BYSI) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a selective immunomodulating microtubule-destabilizing agent designed to stimulate the immune system while affecting tumor-cell biology.

BeyondSpring has evaluated plinabulin for the prevention of chemotherapy-induced neutropenia, a potentially serious complication of cancer treatment, and for use in combination with other therapies in oncology, including treatment approaches for non-small cell lung cancer. The candidate has been studied in late-stage clinical development, although regulatory and development outcomes may vary by indication and jurisdiction.

Founded in 2010, BeyondSpring has pursued a global drug-development strategy with clinical and regulatory activities involving the United States, China and other international markets. The company was co-founded and is led by Lan Huang, Ph.D., who has served as its chief executive officer and has been associated with the company’s research and development programs.

View BeyondSpring Profile